Prognostic role for diffusion-weighted imaging of pediatric optic pathway glioma

• Published in: Journal of neuro-oncology Vol. 113; no. 3; pp. 479 - 483
• Main Authors: Yeom, K. W., Lober, R. M., Andre, J. B., Fisher, P. G., Barnes, P. D., Edwards, M. S. B., Partap, S.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.07.2013; Springer Nature B.V
• Subjects: Brain Neoplasms - mortality; Brain Neoplasms - pathology; Child; Child, Preschool; Clinical Study; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Infant; Male; Medicine; Medicine & Public Health; Neurology; Oncology; Optic Nerve Glioma - mortality; Optic Nerve Glioma - pathology; Prognosis; Survival Rate; ADC; Optic pathway glioma; MRI; DWI
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-013-1140-4

Optic pathway glioma (OPG) has an unpredictable course, with poor correlation between conventional imaging features and tumor progression. We investigated whether diffusion-weighted MRI (DWI) predicts the clinical behavior of these tumors. Twelve children with OPG (median age 2.7 years; range 0.4–6.2 years) were followed for a median 4.4 years with DWI. Progression-free survival (time to requiring therapy) was compared between tumors stratified by apparent diffusion coefficient (ADC) from initial pre-treatment scans. Tumors with baseline ADC greater than 1,400 × 10 −6  mm 2 /s required treatment earlier than those with lower ADC (log-rank p  = 0.002). In some cases, ADC increased leading up to treatment, and declined following treatment with surgery, chemotherapy, or radiation. Baseline ADC was higher in tumors that eventually required treatment (1,562 ± 192 × 10 −6  mm 2 /s), compared with those conservatively managed (1,123 ± 114 × 10 −6  mm 2 /s) (Kruskal–Wallis test p  = 0.013). Higher ADC predicted earlier tumor progression in this cohort and in some cases declined after therapy. Evaluation of OPG with DWI may therefore be useful for predicting tumor behavior and assessing treatment response.